Cargando…

Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen

To improve the prognosis of glioblastoma, we developed an adjuvant treatment directed to a neglected aspect of glioblastoma growth, the contribution of nonmalignant monocyte lineage cells (MLCs) (monocyte, macrophage, microglia, dendritic cells) that infiltrated a main tumor mass. These nonmalignant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salacz, Michael E, Kast, Richard E, Saki, Najmaldin, Brüning, Ansgar, Karpel-Massler, Georg, Halatsch, Marc-Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854261/ https://www.ncbi.nlm.nih.gov/pubmed/27175087 http://dx.doi.org/10.2147/OTT.S100407

Ejemplares similares

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen
por: Kast, Richard E, et al.
Publicado: (2017)

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014)

Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen
por: Kast, Richard E., et al.
Publicado: (2018)

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
por: Pala, Andrej, et al.
Publicado: (2012)

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
por: Kast, Richard E, et al.
Publicado: (2017)

Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme
por: Karpel-Massler, Georg, et al.
Publicado: (2010)

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
por: Kast, Richard E., et al.
Publicado: (2022)

A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen
por: Kast, Richard E., et al.
Publicado: (2020)

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
por: Pruss, Maximilian, et al.
Publicado: (2020)

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
por: Karpel-Massler, Georg, et al.
Publicado: (2014)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Granular Formation during Apoptosis in Blastocystis sp. Exposed to Metronidazole (MTZ)
por: Dhurga, Devi Balkrishnan, et al.
Publicado: (2016)

The limitations of targeting MEK signalling in Glioblastoma therapy
por: Selvasaravanan, Karthika D., et al.
Publicado: (2020)

Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas
por: von Knebel Doeberitz, Nikolaus, et al.
Publicado: (2022)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

The effects of PI3K-mediated signalling on glioblastoma cell behaviour
por: Langhans, Julia, et al.
Publicado: (2017)

Preparation of Poly(MTZ)(n)–(DMAEMA)(m) Micelles and Study on Their Antibacterial Property
por: Zhang, Long, et al.
Publicado: (2020)

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
por: Kast, Richard E., et al.
Publicado: (2013)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

Targeting super-enhancers reprograms glioblastoma central carbon metabolism
por: Nguyen, Trang T.T., et al.
Publicado: (2021)

Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma
por: Thi Thu Nguyen, Trang, et al.
Publicado: (2020)

Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach
por: Mettang, Melanie, et al.
Publicado: (2018)

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
por: Kast, Richard E., et al.
Publicado: (2021)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Novel Conducting and Biodegradable Copolymers with Noncytotoxic Properties toward Embryonic Stem Cells
por: da Silva, Aruã C., et al.
Publicado: (2018)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Targeting cellular respiration as a therapeutic strategy in glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2023)

The CD8(+) T Cell Noncytotoxic Antiviral Responses
por: Morvan, Maelig G., et al.
Publicado: (2021)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
por: Kast, Richard E.
Publicado: (2018)

Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells
por: Hasslacher, Sebastian, et al.
Publicado: (2018)

Noncytotoxic functions of killer cell granzymes in viral infections
por: de Jong, Lisanne C., et al.
Publicado: (2021)

Noncytotoxic silver nanoparticles as a new antimicrobial strategy
por: Skóra, Bartosz, et al.
Publicado: (2021)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Comment in Response to “Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina”
por: Westhoff, Mike-Andrew, et al.
Publicado: (2020)

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g86eo1o92b4bcus60l5d15p4pj